JP2014503206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503206A5 JP2014503206A5 JP2013544747A JP2013544747A JP2014503206A5 JP 2014503206 A5 JP2014503206 A5 JP 2014503206A5 JP 2013544747 A JP2013544747 A JP 2013544747A JP 2013544747 A JP2013544747 A JP 2013544747A JP 2014503206 A5 JP2014503206 A5 JP 2014503206A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant
- adenoviral
- adenoviral vector
- vector
- antigen protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (12)
- 第一および第二の組換えアデノウイルスベクターであり、各々はフィロウイルス抗原タンパク質がコードされる核酸を含み、第一のアデノウイルスベクターには、アデノウイルス26カプシドタンパク質が含まれ、および第二のアデノウイルスベクターには、アデノウイルス35カプシドタンパク質が含まれ、対象に、プライミングワクチン投与として、前記第一の組換えアデノウイルスベクターの免疫学的に効果的な量が施されること;次いで、対象に、ブースティングワクチン投与として、前記第二の組換えアデノウイルスベクターの免疫学的に効果的な量を施すことが続けられることによる、対象での前記フィロウイルス抗原に対する免疫反応の誘導における使用のためのものである、アデノウイルスベクター。
- アデノウイルスベクターは筋肉内に施されるものである、請求項1に記載の組換えアデノウイルスベクター。
- アデノウイルス26カプシドタンパク質を含むアデノウイルスベクターはrAd26ベクターであり、およびアデノウイルス35カプシドタンパク質を含むアデノウイルスベクターはrAd35ベクターである、請求項1または2に記載の組換えアデノウイルスベクター。
- フィロウイルス抗原タンパク質は糖タンパク質である、請求項1〜3のいずれか一項に記載の組換えアデノウイルスベクター。
- フィロウイルス抗原タンパク質はエボラウイルス由来である、請求項1〜4のいずれか一項に記載の組換えアデノウイルスベクター。
- エボラウイルスはザイール種である、請求項5に記載の組換えアデノウイルスベクター。
- フィロウイルス抗原タンパク質は配列番号1に示されるようにポリヌクレオチド配列によってコードされる、請求項6に記載の組換えアデノウイルスベクター。
- エボラウイルスはスーダン/グル種である、請求項5に記載の組換えアデノウイルスベクター。
- フィロウイルス抗原タンパク質は配列番号2に示されるようにポリヌクレオチド配列によってコードされる、請求項8に記載の組換えアデノウイルスベクター。
- フィロウイルス抗原タンパク質は配列番号3に示されるようにポリヌクレオチド配列によってコードされる、請求項8に記載の組換えアデノウイルスベクター。
- フィロウイルス抗原タンパク質はマールブルグウイルス由来である、請求項1〜4のいずれか一項に記載の組換えアデノウイルスベクター。
- フィロウイルス抗原タンパク質は配列番号4に示されるようにポリヌクレオチド配列によってコードされる、請求項11に記載の組換えアデノウイルスベクター。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42295410P | 2010-12-14 | 2010-12-14 | |
US61/422,954 | 2010-12-14 | ||
PCT/US2011/064944 WO2012082918A1 (en) | 2010-12-14 | 2011-12-14 | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016206679A Division JP6268258B2 (ja) | 2010-12-14 | 2016-10-21 | アデノウイルス血清型26および血清型35のフィロウイルスワクチン |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014503206A JP2014503206A (ja) | 2014-02-13 |
JP2014503206A5 true JP2014503206A5 (ja) | 2015-01-29 |
JP6054876B2 JP6054876B2 (ja) | 2016-12-27 |
Family
ID=46245095
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013544747A Active JP6054876B2 (ja) | 2010-12-14 | 2011-12-14 | アデノウイルス血清型26および血清型35のフィロウイルスワクチン |
JP2016206679A Active JP6268258B2 (ja) | 2010-12-14 | 2016-10-21 | アデノウイルス血清型26および血清型35のフィロウイルスワクチン |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016206679A Active JP6268258B2 (ja) | 2010-12-14 | 2016-10-21 | アデノウイルス血清型26および血清型35のフィロウイルスワクチン |
Country Status (14)
Country | Link |
---|---|
US (1) | US9701718B2 (ja) |
EP (1) | EP2655604B1 (ja) |
JP (2) | JP6054876B2 (ja) |
KR (1) | KR101879892B1 (ja) |
CN (1) | CN103370411B (ja) |
AU (1) | AU2011343798B2 (ja) |
BR (1) | BR112013014712B1 (ja) |
CA (1) | CA2821289C (ja) |
DK (1) | DK2655604T3 (ja) |
EA (1) | EA029504B1 (ja) |
ES (1) | ES2676196T3 (ja) |
PL (1) | PL2655604T3 (ja) |
WO (1) | WO2012082918A1 (ja) |
ZA (1) | ZA201304260B (ja) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA029504B1 (ru) | 2010-12-14 | 2018-04-30 | Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретэри Оф Дзе Департмент Оф Хелт Энд Хьюмэн Сервисиз | Способ индуцирования иммунного ответа против филовирусного антигена у пациента с использованием аденовирусов серотипа 26 и серотипа 35 |
AU2015279089B2 (en) | 2014-06-26 | 2021-01-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
EP3656395B1 (en) | 2014-09-03 | 2023-11-08 | Bavarian Nordic A/S | Methods and compositions for inducing protective immunity against filovirus infection |
EA201790507A1 (ru) | 2014-09-03 | 2017-07-31 | Бавариан Нордик А/С | Способы и композиции для усиления иммунных ответов |
HUE053585T2 (hu) | 2014-09-26 | 2021-07-28 | Beth Israel Deaconess Medical Ct Inc | Eljárások és készítmények humán immundeficiencia vírus fertõzés elleni védõ immunválasz indukálására |
WO2016146844A1 (en) | 2015-03-18 | 2016-09-22 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
TWI792091B (zh) | 2015-12-15 | 2023-02-11 | 荷蘭商傑森疫苗防護公司 | 人類免疫缺陷病毒抗原、載體、組成物、及其使用方法 |
CN108697591B (zh) | 2016-02-18 | 2022-06-17 | 国际香料和香精公司 | 聚脲胶囊组合物 |
MX2018011341A (es) | 2016-03-18 | 2019-07-04 | Int Flavors & Fragrances Inc | Microcápsulas de sílice y métodos para prepararlas. |
MA45381A (fr) | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
WO2018011198A1 (en) | 2016-07-15 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
US10925956B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
ES2950434T3 (es) | 2016-09-16 | 2023-10-10 | Int Flavors & Fragrances Inc | Composiciones de microcápsula estabilizadas con agentes de control de la viscosidad |
US20180085291A1 (en) | 2016-09-28 | 2018-03-29 | International Flavors & Fragrances Inc. | Microcapsule compositions containing amino silicone |
WO2018185732A1 (en) | 2017-04-06 | 2018-10-11 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
US20180346648A1 (en) | 2017-05-30 | 2018-12-06 | International Flavors & Fragrances Inc. | Branched polyethyleneimine microcapsules |
WO2018229711A1 (en) | 2017-06-15 | 2018-12-20 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
WO2019018724A1 (en) | 2017-07-21 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS |
KR20200037818A (ko) | 2017-07-28 | 2020-04-09 | 얀센 백신스 앤드 프리벤션 비.브이. | 이종성 repRNA 면역접종을 위한 방법 및 조성물 |
EP3713599A1 (en) | 2017-11-20 | 2020-09-30 | Janssen Pharmaceuticals, Inc. | Method of providing safe administration of adenoviral vectors encoding a zika virus antigen |
AU2018389786A1 (en) | 2017-12-19 | 2020-06-18 | Bavarian Nordic A/S | Methods and compositions for inducing an immune response against hepatitis B virus (HBV) |
WO2020016394A1 (en) | 2018-07-20 | 2020-01-23 | Janssen Vaccines & Prevention B.V. | Recombinant adenoviral vector expressing zika antigen with improved productivity |
CN112770770A (zh) | 2018-09-25 | 2021-05-07 | 扬森疫苗与预防公司 | 共定位施用疫苗组分诱导针对人类免疫缺陷病毒的免疫应答的方法 |
BR112021011903A2 (pt) | 2018-12-18 | 2021-08-31 | International Flavors & Fragrances Inc. | Composição de microcápsula, produto de consumo, e, processo para preparar uma composição de microcápsula |
CA3140255A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Efficient impurity removal using a diafiltration process |
BR112022014808A2 (pt) | 2020-01-31 | 2022-09-20 | Beth Israel Deaconess Medical Ct Inc | Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2 |
CA3183086A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
CN116096406A (zh) | 2020-06-29 | 2023-05-09 | 扬森疫苗与预防公司 | 针对呼吸道合胞病毒感染的疫苗组合 |
EP4175971A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
CN116367854A (zh) | 2020-07-08 | 2023-06-30 | 杨森科学爱尔兰无限公司 | 针对hbv的rna复制子疫苗 |
WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
JP2024509756A (ja) | 2021-02-19 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前rsv fb抗原 |
EP4314019A2 (en) | 2021-04-01 | 2024-02-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
EP4124383A1 (en) | 2021-07-27 | 2023-02-01 | International Flavors & Fragrances Inc. | Biodegradable microcapsules |
WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
EP4154974A1 (en) | 2021-09-23 | 2023-03-29 | International Flavors & Fragrances Inc. | Biodegradable microcapsules |
WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
WO2024061757A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
WO2024061753A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6852324B1 (en) * | 1997-12-23 | 2005-02-08 | The United States Of America As Represented By The Department Of Health And Human Services | Immunization for ebola virus infection |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
DE60226911D1 (de) | 2001-10-01 | 2008-07-10 | Us Health | Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten |
NZ534865A (en) | 2002-04-25 | 2008-07-31 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
ES2335657T3 (es) | 2002-04-25 | 2010-03-31 | Crucell Holland B.V. | Medios y metodos para la produccion de vectores de adenovirus. |
WO2004037294A2 (en) * | 2002-10-23 | 2004-05-06 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
WO2005012538A2 (en) * | 2003-08-01 | 2005-02-10 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Accelerated vaccination |
WO2006037038A1 (en) * | 2004-09-27 | 2006-04-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Optimized vaccines to provide protection against ebola and other viruses |
DE602005025512D1 (de) * | 2004-10-13 | 2011-02-03 | Crucell Holland Bv | Verbesserte adenovirusvektoren und deren verwendung |
BRPI0516048A (pt) | 2004-10-13 | 2008-08-19 | Crucell Holland B V E Beth Isr | batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c |
WO2006040334A1 (en) * | 2004-10-14 | 2006-04-20 | Crucell Holland B.V. | Malaria prime/boost vaccines |
WO2007104792A2 (en) * | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
WO2007110409A1 (en) * | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
WO2009092113A2 (en) * | 2008-01-19 | 2009-07-23 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the delivery of vaccines to disrupted epithelium |
EA029504B1 (ru) | 2010-12-14 | 2018-04-30 | Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретэри Оф Дзе Департмент Оф Хелт Энд Хьюмэн Сервисиз | Способ индуцирования иммунного ответа против филовирусного антигена у пациента с использованием аденовирусов серотипа 26 и серотипа 35 |
-
2011
- 2011-12-14 EA EA201390866A patent/EA029504B1/ru not_active IP Right Cessation
- 2011-12-14 CN CN201180067429.7A patent/CN103370411B/zh active Active
- 2011-12-14 CA CA2821289A patent/CA2821289C/en active Active
- 2011-12-14 BR BR112013014712-1A patent/BR112013014712B1/pt active IP Right Grant
- 2011-12-14 PL PL11849865T patent/PL2655604T3/pl unknown
- 2011-12-14 WO PCT/US2011/064944 patent/WO2012082918A1/en active Application Filing
- 2011-12-14 AU AU2011343798A patent/AU2011343798B2/en active Active
- 2011-12-14 KR KR1020137016833A patent/KR101879892B1/ko active IP Right Grant
- 2011-12-14 ES ES11849865.8T patent/ES2676196T3/es active Active
- 2011-12-14 JP JP2013544747A patent/JP6054876B2/ja active Active
- 2011-12-14 EP EP11849865.8A patent/EP2655604B1/en active Active
- 2011-12-14 DK DK11849865.8T patent/DK2655604T3/en active
- 2011-12-14 US US13/994,532 patent/US9701718B2/en active Active
-
2013
- 2013-06-10 ZA ZA2013/04260A patent/ZA201304260B/en unknown
-
2016
- 2016-10-21 JP JP2016206679A patent/JP6268258B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014503206A5 (ja) | ||
Martin et al. | TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice | |
Hassan et al. | A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2 | |
Ewer et al. | A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA | |
JP2016506416A5 (ja) | ||
Richardson et al. | Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates | |
CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
JP2016510989A5 (ja) | ||
JP2014502156A5 (ja) | ||
RU2015135890A (ru) | Композиция вакцины | |
WO2006063101A3 (en) | Vaccines for the rapid response to pandemic avian influenza | |
JP2019530462A5 (ja) | ||
JP2015533841A5 (ja) | ||
JP2016539946A5 (ja) | ||
JP2012126742A5 (ja) | ||
JP2018518457A5 (ja) | ||
JP2011530309A5 (ja) | ||
JP2014516536A5 (ja) | ||
JP2019519252A5 (ja) | ||
JP2013507907A5 (ja) | ||
MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
JP2015057052A5 (ja) | ||
RU2017113571A (ru) | Рекомбинантные вакцины от fmdv и их применение | |
JP2005523318A5 (ja) | ||
JP2017528158A5 (ja) |